Costs of rheumatoid arthritis in Hungary

Journal of Rheumatology

Volumn 34, Issue 6, 2007, Pages 1437-1439

  Péntek, Márta ^a   Kobelt, Gisela ^b,c   Czirják, László ^d   Szekanecz, Zoltán ^e   Poór, Gyula ^f   Rojkovich, Bernadette ^g   Polgár, Anna ^f   Genti, György ^h   Kiss, Csaba György ^d   Brodszky, Valentin ⁱ   Májer, István ⁱ   Gulácsi, László ⁱ  

^a Pest Megyei Flor Ferenc Korhaz   (Hungary)

^b University of Lund ^*

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF PÉCS   (Hungary)

^e UNIVERSITY OF DEBRECEN   (Hungary)

^f NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^g Flor Ferenc County Hospital ^*  (Hungary)

^h Rheumatology Department   (Hungary)

ⁱ Institute of Data Analytics and Information Systems   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADULT; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; COST; COST EFFECTIVENESS ANALYSIS; DISABILITY; DISEASE ACTIVITY; ECONOMIC ASPECT; FEMALE; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH SERVICE; HEALTH STATUS; HUMAN; HUNGARY; LETTER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS;

EID: 34248335894     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J Rheumatol 2006;33:2124-31.
2. Drummond M, Manca A, Sculpher M. Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 2005;21:165-71.
3. Gulacsi L, Boncz I, Drummond M. Issues for countries considering introducing the "fourth hurdle": The case of Hungary. Int J Technol Assess Health Care 2004;20:337-41.
4. Maetzel A, Tugwell P, Boers M, et al. Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol 2003;30:891-6.
5. Gabriel S, Drummond M, Maetzel A, et al. OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
6. Barton P, Jobanputra P, Wilson J, Bryan S, Burls A. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:iii1-91.
7. Guillemin F, Durieux S, Daurés JP, et al. Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004;31:1297-304.
8. Verstappen SM, Verkleij H, Bijlsma JW, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004;63:817-24.
9. Westhovens R, Boonen A, Verbruggen L, et al. Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin Rheumatol 2005;24:615-9.
10. Hulsemann JL, Ruof J, Zeidler H, Mittendorf T. Costs in rheumatology: results and lessons learned from "Hannover Costing Study". Rheumatol Int 2006;26:704-11.